ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY.

ABSTRACT:

Background/purpose

Anti-vascular endothelial growth factor therapies have proven effective in treating retinal diseases but come with a high financial burden to the patient and health care system. Biosimilar drugs present an opportunity to decrease the cost of these important ophthalmic medications, and several ophthalmic biosimilars are expected to be approved and enter the market in the coming years. The objectives of this review are to educate ophthalmologists on the safety and efficacy of biosimilars in ophthalmology in the United States and European Union, review the biosimilar manufacturing and approval process, and describe the upcoming ophthalmic biosimilars.

Results

Two ranibizumab biosimilars are currently approved in the United States and European Union. Additiona

SUBMITTER: Kaiser PK 

PROVIDER: S-EPMC9665947 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature